We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novo Nordisk, Sanofi Unlikely to Cut Insulin Prices Despite Pressure From Senator
Novo Nordisk, Sanofi Unlikely to Cut Insulin Prices Despite Pressure From Senator
Novo Nordisk and Sanofi, the two largest makers of insulin in the U.S., seem unlikely to budge on pricing despite competitor Eli Lilly’s announcement of price cuts and subsequent letters from Sen. Bernie Sanders (I-Vt.) calling on the two companies to follow suit.